Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches

Temraz, Sally; Alameddine, Raafat; Shamseddine, Ali

doi: 10.1097/CCO.0000000000000184
INNOVATIVE EARLY CLINICAL TRIALS METHODOLOGY AND NEW THERAPEUTICS IN CANCER: Edited by Ahmad Awada
Buy
SDC
Editor's Choice

Purpose of review B-type proto-oncogene (BRAF) mutations have been observed in about 10.8% of patients with colorectal cancer (CRC). These patients do not respond to standard therapy with anti-epidermal growth factor receptor kinase (EGFR). Here we review novel BRAF inhibitors that are currently being investigated in these tumors.

Recent findings Clinical experience with the BRAF inhibitor vemurafenib in CRC suggests significant differences in response compared with melanoma. Based on preclinical data, resistance to BRAF inhibitors employs alternative signaling pathways that in turn induce cell proliferation and survival. Therapeutic strategies that combine BRAF inhibitors in addition to targeted therapy with anti-EGFR monoclonal antibodies and phosphoinositide 3-kinase pathway inhibitors or standard therapy have yielded promising results in preclinical models and some reported cases.

Summary Results from current clinical trials that are exploring novel BRAF inhibitors and others that employ combined therapy are eagerly awaited for the treatment of BRAF-mutated CRC.

Video abstract http://links.lww.com/COON/A13.

Supplemental Digital Content is available in the text

Division of Medical Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Correspondence to Ali Shamseddine, Riad El-Solh, Beirut 1107 2020, Lebanon. Tel: +9611350000 x5390; fax: +961 1 370814; e-mail: as04@aub.edu.lb

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.co-oncology.com).

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.